OmniAb's Q3 revenue falls 47%, net loss widens marginally

OmniAB

04/11/2025 21:56

Overview

OmniAb Q3 2025 revenue misses analyst expectations, declining to $2.2 mln

Net loss for Q3 2025 was $16.5 mln, compared to $16.4 mln in 2024

Company expands technology platform, enters new license agreements

Outlook

OmniAb expects 2025 revenue between $18 mln and $22 mln

Operating expenses for 2025 expected between $82 mln and $86 mln

Company anticipates ending 2025 with $52 mln to $56 mln in cash

Result Drivers

REVENUE DECLINE - Decrease in milestone and service revenue due to completion of small molecule ion channel programs

TECHNOLOGY EXPANSION - Continued expansion of technology platform and new license agreements

PRIVATE PLACEMENT - Strengthened balance sheet through private placement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$2.24 mln
$5.64 mln (7 Analysts)
Q3 EPS
-$0.14
Q3 Net Income
-$16.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for OmniAb Inc is $10.00, about 85.2% above its November 3 closing price of $1.48

Press Release: ID:nBw7xZLN6a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)